REZZAYO 200 mg powder for concentrate for solution for infusion
MR907-2502
Phase 2 small_molecule active
Quick answer
REZZAYO 200 mg powder for concentrate for solution for infusion for Chronic pulmonary aspergillosis (CPA) is a Phase 2 program (small_molecule) at Mundipharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mundipharma GmbH
- Indication
- Chronic pulmonary aspergillosis (CPA)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active